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Abstract 
Background. Statins are used as first-line drugs against hypercholesterolemia after heart transplantation. Randomized 
clinical trials have shown that they reduce cholesterol levels, and the incidence of rejection and coronary 
vasculopathy. Adverse effects have been related to the use of certain statins, high statin dosages, comorbidities, and 
coadministration with cyclosporine. However, estimation of the risk of adverse effects for a given patient is difficult. 
The aims of this study were to determine the incidence of various kinds of adverse effect of statins; to evaluate 
certain potential risk factors; and to assess the efficacy of early response to signs of adverse effects. 
Methods. Between April 1991 and December 2003, we retrospectively evaluated 336 heart transplant patients 
(including 55 women) with regard to the occurrence of possible adverse effects of statins (rhabdomyolysis, myalgia, 
hepatotoxicity, high CK without muscle symptoms, and others). Resolution on reduction of dosage or discontinuance 
and/or change of statin were deemed to constitute confirmation of cause. Relations were sought between adverse 
effects and age, sex, immunosuppressive therapy, kidney failure, body mass index (BMI), arterial hypertension, and 
diabetes mellitus. 
Results. Possible adverse events of statins were suffered by 60 patients, all of them men. The causal role of statins 
was confirmed in 41 (12.2% of all 336): hepatotoxicity was suffered by 13, high CK without muscle ache or 
weakness by 18, rhabdomyolysis by 5, myalgia by 3, and other effects by 2. The incidence of confirmed statin-related 
complications was higher among patients with BMI >29 kg/m2 than among those with lower BMI (P = .055). None 
of the patients with confirmed statin-related complications needed dialysis, none died, and permanent suspension of 
statin treatment was only necessary in 13 cases (3.9% of the 336). 
Conclusions. Some 10% to 20% of HT patients appear to suffer adverse side effects of initial statin therapy. 
However, early detection of such effects through diligent clinical and analytical monitoring allows the therapy to be 
modified in time to minimize the appearance of severe complications. In only a minority of cases permanent 
suspension of statin therapy is necessary. 
Hypercholesterolemia is common after heart transplantation (HT); 60% to 80% of HT patients 
showing increased dyslipidemia after transplant.1 High cholesterol levels have been associated with 
rejection, the development of coronary vasculopathy, impaired endothelial function, myocardial infarct, 
and death.2 Randomized clinical trials3, 4, 5, 6, 7, 8 and 9 have shown that the use of statins (inhibitors of 3-
hydroxy-3-methylglutaryl coenzyme A reductase) reduce blood cholesterol levels and coronary disease 
following HT. In our institution, statins are considered to be an important component of early 
posttransplant therapy. Lipid-lowering treatment may occasionally lead to adverse effects, especially 
when it involves certain statins or high doses, or when it coincides with cyclosporine therapy.10 It is 
desirable to be able to estimate the risk of such effects for an individual patient from consideration of risk 
factors. The aims of this study of 336 statin-treated HT patients were to determine the incidence of 
various kinds of adverse effect of statins; to evaluate certain potential risk factors; and to assess the 
efficacy of early response to signs of adverse effects. 
Methods 
Between April 1991 and December 2003, 444 patients received heart transplants in our institution. We 
retrospectively evaluated the 336 who were older than 16 years at HT and who after HT had survived for 
more than 1 month and received lipid-lowering therapy with statins. In all cases, adverse effects of statin 
treatment was monitored by routine laboratory determinations of creatine kinase (CK), alanine transferase 
(ALT), and aspartate transferase (AST) every 3 months, or every 4 weeks if the statin dose had been 
increased, and by periodic clinical examination. The following conditions were noted as possible adverse 
effects of statins: rhabdomyolysis (CK >1000 U/L); high CK (CK <1000 U/L but greater than three times 
previous level, without muscle symptoms); hepatotoxicity (AST or ALT levels greater than three times 
the previous level or twice the upper limit of the normal range); myalgia (muscle ache without CK 
elevation); and others (increase in LDH or bilirubin levels). The therapeutic response to the appearance of 
these conditions was to reduce the statin dosage; to suspend statin treatment for as long as was required to 
resolve the symptoms; or to change the statin, either immediately or after temporary suspension of 
treatment. They were attributed to the use of statins if they resolved when so treated. Other data noted for 
each patient were age, gender, immunosuppressive therapy, body mass index (BMI), and whether the 
patient had arterial hypertension, kidney failure, or diabetes mellitus. 
Results 
Of 336 patients (mean age 53 years), 55 were women (16.4%). Statin therapy was initiated with 
pravastatin in 269 cases (80.1%), simvastatin in 65 (19.3%), and atorvastatin in 2 (0.6%). Thirty-one 
patients (9.2%) had diabetes mellitus before HT, and 65 (19.3%) had a BMI >29 kg/m2. More than 50% 
(172 patients) had arterial hypertension after HT. 
Possible adverse effects of statins were observed in 60 of the 336 statin-treated patients (17.9%), all of 
them men: hepatotoxicity in 26 (7.7% of the 336), high CK without muscle ache or weakness in 20 
(6.0%), rhabdomyolysis in 6 (1.8%), myalgia in 4 (1.2%), and other effects in 4 (1.2%). In 3 of these 60 
cases (5%), the statin dosage was reduced but not suspended; in 11 (18.3%) treatment was suspended 
temporarily and resumed with the same drug; in 18 (30%) treatment was suspended temporarily and later 
resumed with another statin; in 6 (10%) the statin was changed without prior suspension of treatment; and 
in 22 (36.7%) statin treatment was suspended indefinitely. 
In 41 of the 60 cases in which possible adverse effects of statins were observed, resolution of these 
effects led to their being attributed to statin treatment. In 13 of these 41 cases (3.87% of the 336 statin-
treated patients), the effect was hepatotoxicity, in 18 (5.36%) high CK without muscle ache or weakness, 
in 5 (1.49%) rhabdomyolysis, in 3 (0.89%) myalgia, and in 2 (0.59%) other effects. 
Among the 336 statin-treated patients, the incidence of confirmed adverse effects was greater when 
BMI >29 kg/m2, but the difference was not statistically significant (P = .055). Of the 41 patients with 
confirmed adverse effects, 19 were receiving cyclosporine, prednisone, and mycophenolate mofetil 
immunosuppressive therapy (46.3%); 11 were taking cyclosporine, prednisone, and azathioprine (26.8%); 
and 6 were taking tacrolimus, prednisone, and mycophenolate mofetil (14.6%). The occurrence of adverse 
effects was not correlated with immunosuppressive therapy, diabetes mellitus, age, arterial hypertension, 
or renal dysfunction. 
In 20 of the 41 patients with confirmed adverse effects of statin, the statin apparently responsible was 
pravastatin (7.43% of pravastatin-treated patients), but in our study, as in other studies11 this drug was in 
no case associated with severe adverse effects. Simvastatin was apparently responsible for seven cases of 
adverse effects (10.76% of simvastatin-treated patients), including four of the five cases of 
rhabdomyolysis. The other one that developed rhabdomyolysis was initially put on atorvastatin. However, 
none of the 41 patients with confirmed adverse effects of statins needed dialysis, and none died. In 3 of 
these 41 cases, resolution of symptoms followed dose reduction, in 3, an immediate change of statin, in 8, 
temporary suspension followed by resumption with the same statin, and in 14, temporary suspension 
followed by resumption with a different statin; in 13 cases, statin treatment was not resumed. 
Discussion 
Aggressive statin therapy after heart transplantation has in several trials been found to reduce 
cholesterol levels, the incidence of major rejection, the incidence of coronary vasculopathy, and mortality. 
Therefore, treatment with statins is recommended for all HT patients in the absence of contraindications. 
However, statin treatment has its risks, including the possibility of fatal rhabdomyolysis. Although the 
estimated incidence of fatal rhabdomyolysis per 1 million prescriptions among patients of all kinds is zero 
for fluvastatin and only 0.04 for pravastatin, 0.12 for simvastatin, and 0.19 for lovastatin,12 the 
corresponding incidences among HT patients are probably higher, because the risk factors for 
complications of statin therapy include treatment with drugs commonly employed in post-HT therapy, 
such as cyclosporine. Other reported risk factors include advanced age, small or frail constitution, chronic 
kidney failure, abuse of ethanol, recent surgical operation, and high consumption of grapefruit 
juice.13 and 14 Ideally, the risk of complications of individual patients should be estimated, and the type and 
dosage of statin chosen accordingly. 
Some of the complications of statin therapy, notably liver damage, can also be caused by other drugs 
taken by HT patients. If these complications arise in HT patients, they cannot automatically be assumed 
to be secondary to statin treatment. In this study, complications were therefore deemed a result of statin 
treatment only if they resolved on reduction of dosage, suspension of treatment, or change of statin. 
In this study it was not the general rule for patients to suffer adverse effects of statins, but the 
incidence was not so low as in some other studies,6, 7, 8, 9 and 14 even when we considered only cases in 
which the attribution to statin treatment was confirmed by remission. This was probably because the CK 
and transaminase thresholds used to define adverse effects were lower than those used in other studies. By 
contrast, in this study the incidence of severe adverse effects (death or kidney dysfunction requiring 
dialysis) was zero, which suggests that early diagnosis and an appropriate response can avoid advanced 
complications. 
Although all adverse effects concerned men, this finding should be viewed with caution because there 
were only 55 women in the study group (16.4%). Although the difference in incidence of adverse effects 
between patients with BMI >29 kg/m2 and those with BMI <29 kg/m2 lacked a few tenths of a percentage 
point to be regarded as statistically significant, the higher incidence among those with greater BMI should 
probably be kept in mind in evaluating individual patients. 
In conclusion, statins should be considered as first-line drugs against hypercholesterolaemia and its 
consequences following heart transplantation. The low incidence of severe complications in this study 
confirms that these drugs are safe if the patient’s response is monitored by clinical examinations and 
laboratory tests, if appropriate marker thresholds are used to warn of the onset of adverse effects, and if 
appropriate action is taken in response to positive results of these tests or examinations. 
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